Meta-Flux

Based in Ireland, Meta-Flux utilizes AI and multi-disciplinary expertise to innovate drug development through its advanced technology platform, aimed at enhancing the efficiency of biomedical research. Meta-Flux, founded in 2021 and headquartered in Dublin, Ireland, focuses on advancing drug development using artificial intelligence. The company has completed one funding deal, raising EUR 1. 8 million in Seed funding on October 13, 2025, to enhance its platform capabilities.

Meta-Flux is centered around its flagship product, the AI Biologist, a structured neural network platform designed to revolutionize drug development. This platform leverages advanced artificial intelligence and bioinformatics to streamline and enhance the drug discovery process, particularly focusing on areas such as immunology, oncology, and respiratory diseases. The AI Biologist is intended for use by pharmaceutical companies, biotech firms, and research institutions, offering capabilities that assist in model development, data analysis, and predictive analytics for drug efficacy and safety. The solution is marketed primarily in North America and Europe, targeting organizations that are engaged in biomedical research and drug innovation.

The revenue model for Meta-Flux is primarily structured around B2B transactions, where the company collaborates with pharmaceutical and biotech firms to provide access to its AI Biologist platform. Clients typically engage in subscription agreements, which offer tiered access to different features and capabilities of the platform based on their specific needs. These partnerships may also include consulting services for tailored solutions in drug development. The pricing plans are designed to accommodate varying scales of operations, ensuring that both large enterprises and smaller biotech startups can leverage the AI Biologist for their research objectives.

This transactional structure aligns with the growing demand for AI-driven tools in drug development, supporting clients in achieving efficient and innovative outcomes in their therapeutic pursuits. In October 2025, Meta-Flux raised EUR 1. 8 million in Seed funding, with individual investors participating in the round. The company plans to utilize this funding to expand its decision-support platform for preclinical drug development, bridging the gap between preclinical research and clinical application.

Future growth strategies include launching new product features and expanding into additional markets across Europe and North America by 2026.